Squarepoint Ops LLC Buys 53,807 Shares of Omnicell, Inc. $OMCL

Squarepoint Ops LLC boosted its stake in shares of Omnicell, Inc. (NASDAQ:OMCL) by 80.8% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 120,419 shares of the company’s stock after buying an additional 53,807 shares during the period. Squarepoint Ops LLC owned approximately 0.26% of Omnicell worth $5,000,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the stock. AQR Capital Management LLC grew its stake in shares of Omnicell by 42.1% in the first quarter. AQR Capital Management LLC now owns 17,936 shares of the company’s stock worth $627,000 after acquiring an additional 5,311 shares during the last quarter. Empowered Funds LLC raised its position in shares of Omnicell by 14.3% in the 1st quarter. Empowered Funds LLC now owns 9,953 shares of the company’s stock worth $348,000 after purchasing an additional 1,243 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Omnicell by 4.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 124,047 shares of the company’s stock worth $4,337,000 after purchasing an additional 4,866 shares in the last quarter. Jane Street Group LLC grew its position in Omnicell by 201.5% during the 1st quarter. Jane Street Group LLC now owns 163,664 shares of the company’s stock valued at $5,722,000 after purchasing an additional 109,382 shares during the last quarter. Finally, Creative Planning grew its position in Omnicell by 16.7% during the 2nd quarter. Creative Planning now owns 9,390 shares of the company’s stock valued at $276,000 after purchasing an additional 1,347 shares during the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. KeyCorp reaffirmed an “overweight” rating on shares of Omnicell in a report on Monday, August 24th. Zacks Research upgraded shares of Omnicell from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Wells Fargo & Company reduced their price target on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Piper Sandler reaffirmed an “overweight” rating and issued a $45.00 price objective (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Finally, Weiss Ratings upgraded Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, August 18th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $57.86.

Omnicell Stock Up 1.7%

Shares of Omnicell stock opened at $32.79 on Friday. The company has a market cap of $1.49 billion, a price-to-earnings ratio of 39.04, a price-to-earnings-growth ratio of 0.81 and a beta of 0.97. The company’s 50 day moving average is $38.47 and its 200 day moving average is $39.07. Omnicell, Inc. has a twelve month low of $29.06 and a twelve month high of $55.00. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.47. The company had revenue of $312.21 million for the quarter, compared to analysts’ expectations of $310.21 million. Omnicell had a net margin of 3.13% and a return on equity of 5.66%. The firm’s quarterly revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the company posted $0.45 earnings per share. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Research analysts anticipate that Omnicell, Inc. will post 1.41 EPS for the current year.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.